{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:13:23Z","timestamp":1791465203348,"version":"4.3.4"},"reference-count":37,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"accepted":{"date-parts":[[2025,7,29]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To explore the association between early response of different lesions and the number of anti-vascular endothelial growth factor (anti-VEGF) injections in neovascular age-related macular degeneration (nAMD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective study included treatment-na\u00efve nAMD eyes with a 2-year follow-up period. Volumetric changes of multiple lesions during the loading phase were documented, including subretinal fluid (SRF), intraretinal fluid (IRF), vascular subretinal hyper-reflective material (vSHRM) and avascular subretinal hyper-reflective material, fibrovascular pigment epithelial detachment and serous pigment epithelial detachment (sPED) and total lesion. Imaging biomarkers associated with treatment frequency were analysed for 1-year and 2-year periods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 92 eyes (92 patients) were included, with a mean age of 65.77\u00b17.28 years. During the loading phase, all lesions except vSHRM showed significant temporal changes (p&lt;0.05). Multivariate regression revealed that greater SRF changes at month 3 and IRF changes at month 1 were associated with increased injection frequency for both 1-year (\u03b2=0.353\u2009and 0.360, p=0.025\u2009and 0.022) and 2-year periods (\u03b2=0.336\u2009and 0.293, p=0.004\u2009and 0.026). Conversely, greater changes in vSHRM and sPED at month 2 were associated with fewer first-year injections (\u03b2=\u22120.307\u2009and \u22120.697, p=0.023\u2009and 0.022), while sPED changes at months 2 and 3 correlated with reduced 2-year requirements (\u03b2=\u22120.845\u2009and \u22120.297, p=0.005\u2009and 0.031).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Enhanced absorption of SRF and IRF during early treatment was associated with increased injection frequency, while greater absorption of vSHRM and sPED correlated with reduced treatment requirements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ChiCTR2200063428.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bjo-2025-327339","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T09:20:35Z","timestamp":1755163235000},"page":"67-75","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Association between early lesion response and long-term anti-VEGF injection frequency in nAMD: a 2-year prospective study using 3D volumetric analysis"],"prefix":"10.1136","volume":"110","author":[{"given":"Jiaxin","family":"Pu","sequence":"first","affiliation":[{"name":"Sun Yat-Sen University Zhongshan Ophthalmic Center State Key Laboratory of Ophthalmology, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuenan","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Sun Yat-Sen University Zhongshan Ophthalmic Center State Key Laboratory of Ophthalmology, Guangzhou, Guangdong, China"},{"name":"Ophthalmology, Guangdong Provincial People\u2019s Hospital, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1630-7555","authenticated-orcid":false,"given":"Miaoling","family":"Li","sequence":"additional","affiliation":[{"name":"Sun Yat-Sen University Zhongshan Ophthalmic Center State Key Laboratory of Ophthalmology, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5530-4202","authenticated-orcid":false,"given":"Xiongze","family":"Zhang","sequence":"additional","affiliation":[{"name":"Sun Yat-Sen University Zhongshan Ophthalmic Center State Key Laboratory of Ophthalmology, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Ji","sequence":"additional","affiliation":[{"name":"Sun Yat-Sen University Zhongshan Ophthalmic Center State Key Laboratory of Ophthalmology, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Mi","sequence":"additional","affiliation":[{"name":"Sun Yat-Sen University Zhongshan Ophthalmic Center State Key Laboratory of Ophthalmology, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlei","family":"Hao","sequence":"additional","affiliation":[{"name":"Sun Yat-Sen University Zhongshan Ophthalmic Center State Key Laboratory of Ophthalmology, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiqin","family":"He","sequence":"additional","affiliation":[{"name":"Sun Yat-Sen University Zhongshan Ophthalmic Center State Key Laboratory of Ophthalmology, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyue","family":"Su","sequence":"additional","affiliation":[{"name":"Sun Yat-Sen University Zhongshan Ophthalmic Center State Key Laboratory of Ophthalmology, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Gan","sequence":"additional","affiliation":[{"name":"Sun Yat-Sen University Zhongshan Ophthalmic Center State Key Laboratory of Ophthalmology, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yining","family":"Zhang","sequence":"additional","affiliation":[{"name":"Sun Yat-Sen University Zhongshan Ophthalmic Center State Key Laboratory of Ophthalmology, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelin","family":"Chen","sequence":"additional","affiliation":[{"name":"Sun Yat-Sen University Zhongshan Ophthalmic Center State Key Laboratory of Ophthalmology, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3319-4051","authenticated-orcid":false,"given":"Feng","family":"Wen","sequence":"additional","affiliation":[{"name":"Sun Yat-Sen University Zhongshan Ophthalmic Center State Key Laboratory of Ophthalmology, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"2025121502150600000_110.1.67.1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(13)70145-1"},{"key":"2025121502150600000_110.1.67.2","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/aos.15783","article-title":"Treatment burden on patients receiving intravitreal anti\u2010VEGF for wet age\u2010related macular degeneration","volume":"102","author":"Vinge","year":"2024","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"2025121502150600000_110.1.67.3","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2014.884559"},{"key":"2025121502150600000_110.1.67.4","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.2147\/DDDT.S295223","article-title":"Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration","volume":"15","author":"Hussain","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"2025121502150600000_110.1.67.5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000516108","article-title":"Imaging Biomarkers and Their Impact on Therapeutic Decision-Making in the Management of Neovascular Age-Related Macular Degeneration","volume":"244","author":"Wong","year":"2021","journal-title":"Ophthalmologica"},{"key":"2025121502150600000_110.1.67.6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40662-022-00287-1","article-title":"Prediction of the short-term efficacy of anti-VEGF therapy for neovascular age-related macular degeneration using optical coherence tomography angiography","volume":"9","author":"Jia","year":"2022","journal-title":"Eye and Vis"},{"key":"2025121502150600000_110.1.67.7","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.ophtha.2018.01.004","article-title":"Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"125","author":"Daniel","year":"2018","journal-title":"Ophthalmology"},{"key":"2025121502150600000_110.1.67.8","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ophtha.2014.11.007","article-title":"Growth of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials","volume":"122","author":"Grunwald","year":"2015","journal-title":"Ophthalmology"},{"key":"2025121502150600000_110.1.67.9","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.ophtha.2020.06.019","article-title":"Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study","volume":"127","author":"Spooner","year":"2020","journal-title":"Ophthalmology"},{"key":"2025121502150600000_110.1.67.10","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1167\/iovs.16-20637","article-title":"Three-Dimensional Analysis of Morphologic Changes and Visual Outcomes in Neovascular Age-Related Macular Degeneration","volume":"58","author":"Lee","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2025121502150600000_110.1.67.11","doi-asserted-by":"crossref","first-page":"104716","DOI":"10.1016\/j.mvr.2024.104716","article-title":"Association between three-dimensional morphological features and functional indicators of neovascular age-related macular degeneration","volume":"155","author":"Zhuang","year":"2024","journal-title":"Microvasc Res"},{"key":"2025121502150600000_110.1.67.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2024.06.019"},{"key":"2025121502150600000_110.1.67.13","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2024-326319"},{"key":"2025121502150600000_110.1.67.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.11.004"},{"key":"2025121502150600000_110.1.67.15","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.survophthal.2023.10.013","article-title":"Subretinal hyperreflective material in retinal and chorioretinal disorders: A comprehensive review","volume":"69","author":"Feo","year":"2024","journal-title":"Surv Ophthalmol"},{"key":"2025121502150600000_110.1.67.16","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.oret.2024.02.010","article-title":"Compartmental Exudative Dynamics in Neovascular Age-Related Macular Degeneration: Volumetric Outcomes and Impact of Volatility in a Phase III Clinical Trial","volume":"8","author":"Ehlers","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"2025121502150600000_110.1.67.17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1001\/jamaophthalmol.2020.5130","article-title":"Changes in Treatment-Naive Pigment Epithelial Detachments Associated With the Initial Anti-Vascular Endothelial Growth Factor Injection: A Post Hoc Analysis From the HARBOR Trial","volume":"139","author":"Javaheri","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"2025121502150600000_110.1.67.18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ajo.2017.06.015","article-title":"Association of Vascular Versus Avascular Subretinal Hyperreflective Material With Aflibercept Response in Age-related Macular Degeneration","volume":"181","author":"Kawashima","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"2025121502150600000_110.1.67.19","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2013-304670"},{"key":"2025121502150600000_110.1.67.20","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1097\/IAE.0000000000001009","article-title":"RETINAL PIGMENT EPITHELIAL TEAR AFTER INTRAVITREAL RANIBIZUMAB TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION","volume":"36","author":"Cho","year":"2016","journal-title":"Retina"},{"key":"2025121502150600000_110.1.67.21","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/IAE.0b013e3182755793","article-title":"Variable response of vascularized pigment epithelial detachments to ranibizumab based on lesion subtypes, including polypoidal choroidal vasculopathy","volume":"33","author":"Inoue","year":"2013","journal-title":"Retina"},{"key":"2025121502150600000_110.1.67.22","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.oret.2021.12.007","article-title":"Impact of Intra- and Subretinal Fluid on Vision Based on Volume Quantification in the HARBOR Trial","volume":"6","author":"Riedl","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"2025121502150600000_110.1.67.23","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ajo.2015.07.034","article-title":"Baseline Predictors of 12-Month Treatment Response to Ranibizumab in Patients With Wet Age-Related Macular Degeneration","volume":"160","author":"Regillo","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"2025121502150600000_110.1.67.24","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305186"},{"key":"2025121502150600000_110.1.67.25","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1038\/s41433-020-01354-4","article-title":"Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD","volume":"35","author":"Chakravarthy","year":"2021","journal-title":"Eye (Lond)"},{"key":"2025121502150600000_110.1.67.26","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.594087","article-title":"Molecular Biomarkers of Neovascular Age-Related Macular Degeneration With Incomplete Response to Anti-Vascular Endothelial Growth Factor Treatment","volume":"11","author":"Mantel","year":"2020","journal-title":"Front Pharmacol"},{"key":"2025121502150600000_110.1.67.27","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00221","article-title":"Resistance Mechanisms to Anti-angiogenic Therapies in Cancer","volume":"10","author":"Haibe","year":"2020","journal-title":"Front Oncol"},{"key":"2025121502150600000_110.1.67.28","first-page":"2408","article-title":"VEGF-initiated blood-retinal barrier breakdown in early diabetes","volume":"42","author":"Qaum","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2025121502150600000_110.1.67.29","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.4103\/ijo.IJO_3156_20","article-title":"Subretinal hyperreflective material morphology in neovascular age-related macular degeneration: A case control study","volume":"69","author":"Alex","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"2025121502150600000_110.1.67.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.05.042"},{"key":"2025121502150600000_110.1.67.31","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2023-323577"},{"key":"2025121502150600000_110.1.67.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.06.014"},{"key":"2025121502150600000_110.1.67.33","doi-asserted-by":"crossref","DOI":"10.1186\/s12886-023-02797-5","article-title":"Predictive value of pigment epithelial detachment markers for visual acuity outcomes in neovascular age-related macular degeneration","volume":"23","author":"Shu","year":"2023","journal-title":"BMC Ophthalmol"},{"key":"2025121502150600000_110.1.67.34","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/IAE.0000000000000166","article-title":"Subretinal hyperreflective exudation associated with neovascular age-related macular degeneration","volume":"34","author":"Shah","year":"2014","journal-title":"Retina"},{"key":"2025121502150600000_110.1.67.35","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1007\/s11095-016-1940-2","article-title":"Hydrodynamic Radii of Ranibizumab, Aflibercept and Bevacizumab Measured by Time-Resolved Phosphorescence Anisotropy","volume":"33","author":"Hirvonen","year":"2016","journal-title":"Pharm Res"},{"key":"2025121502150600000_110.1.67.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2005.09.004"},{"key":"2025121502150600000_110.1.67.37","doi-asserted-by":"publisher","DOI":"10.1177\/1756285613484079"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjo-2025-327339","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T10:16:27Z","timestamp":1765793787000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjo-2025-327339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,15]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bjo-2025-327339"],"URL":"https:\/\/doi.org\/10.1136\/bjo-2025-327339","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]}}}